CEL-SCI Co. (NYSEAMERICAN:CVM) was the target of a large decline in short interest in the month of December. As of December 29th, there was short interest totalling 510,101 shares, a decline of 3.2% from the December 15th total of 526,760 shares. Based on an average trading volume of 161,531 shares, the short-interest ratio is presently 3.2 days. Approximately 4.6% of the shares of the company are short sold.

CEL-SCI (CVM) opened at $2.15 on Friday. The firm has a market capitalization of $25.44, a PE ratio of -1.33 and a beta of -1.60. CEL-SCI has a twelve month low of $1.46 and a twelve month high of $3.92.

In related news, Director Vicente Benjamin Asuncion sold 160,000 shares of the business’s stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $0.39, for a total value of $62,400.00.

Separately, Dawson James reaffirmed a “neutral” rating on shares of CEL-SCI in a report on Monday, October 16th.

ILLEGAL ACTIVITY NOTICE: “CEL-SCI Co. (CVM) Short Interest Down 3.2% in December” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/01/14/cel-sci-co-cvm-short-interest-down-3-2-in-december.html.

About CEL-SCI

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.